Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report
| Autor: | Carlos Abraira, Thomas E. Moritz, William C. Duckworth |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Blood Glucose
Male medicine.medical_specialty Endocrinology Diabetes and Metabolism Type 2 diabetes Body Mass Index law.invention Endocrinology Randomized controlled trial Risk Factors law Internal medicine Diabetes mellitus Internal Medicine medicine Humans Hypoglycemic Agents Insulin Prospective Studies Risk factor Veterans Affairs Aged Veterans Glycated Hemoglobin business.industry Body Weight Middle Aged medicine.disease Surgery Blood pressure Diabetes Mellitus Type 2 Cardiovascular Diseases Female Rosiglitazone business Body mass index Diabetic Angiopathies medicine.drug |
| Zdroj: | Diabetes, Obesity and Metabolism. 11:150-156 |
| ISSN: | 1463-1326 1462-8902 |
| DOI: | 10.1111/j.1463-1326.2008.00933.x |
| Popis: | Objective: The Veterans Affairs Diabetes Trial (VADT) will assess the effect of intensive (INT) vs improved standard (STD) glycaemic control on major cardiovascular (CV) events, treating other risk factors equally in both arms. Four-year results of main metabolic parameters are presented. Research design and methods: VADT is a 7.5 years prospective randomized study of 1791 patients, 20 centres, of men and women of age 60.5 ± 8.7 years, diagnosed for 11.5 ± 7.5 years. Their body mass index (BMI) at baseline was 31 ± 4 kg/m2 and mean A1C 9.4 ± 1.5% after maximum dose of oral agents or insulin treatment. Step treatment consists of glimepiride or metformin, rosiglitazone, insulin and other agents; A1C goals are 8–9% in STD and |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text